CSF profiling of impaired Blood‐brain barrier individuals: novel putative biomarkers discovery

Abstract Background Blood‐brain barrier (BBB) integrity is crucial for brain homeostasis and maintenance. This is a pilot study to investigate cerebrospinal fluid (CSF) levels of several proteins implicated in BBB integrity, such as aquaporin‐4 (AQP4), platelet‐derived growth factor (PDGFRβ), human major facilitator superfamily domain containing protein 2A (MFSD2A), matrix metalloproteinase (MMP)‐9, Matrix metalloproteinase (MMP)‐2, and Fibrinogen, for assessing BBB integrity. Method CSF samples were collected from 100 participants (36 [36%] female and 64 males [64%]; mean [SD] age, 73,34 [9,05] years). Participants were stratified according to their CSF/serum albumin concentration ratio (Q‐Alb); intact BBB (Q‐Alb <9, n = 25), mild BBB damage (Q‐Alb 9‐14, n = 25), modest BBB damage (Q‐Alb 14‐30, n = 24), and severe BBB damage (Q‐Alb >30, n = 25). AD CSF biomarkers (p‐Tau181, total‐Tau, Aβ42/40 ratio) were assessed by LUMIPULSE G1200. Protein levels were quantified using ELISA Kits (CUSABIO, Thermofisher, Bioss Antibodies). Correlation analyses were conducted between protein levels and albumin CSF/serum ratios with R (Kruskal‐Wallis test with pairwise comparison, Bonferroni method, was performed). Result CSF AQP4 and PDGFRβ levels were significantly higher in individuals with severe BBB damage (Figure 1). No significant differences are highlighted in the levels of MMP9, MMP2, MFSD2A and Fibrinogen; whereas, in both MFSD2A and Fibrinogen it is shown a notable difference in the levels of protein between the modest and intact groups, with a subsequent decline in the severe group. A positive correlation (Figure 2) between PDGFRB and AQP4 with Q‐Alb (PDGFRB, r = 0,273, P < 0,0001; AQP4, r = 038, P < 0,001) was found, where AQP4 seems to best reflect albumin stratification (Figure 3). Conclusion In this pilot study, we show that CSF concentration of some blood‐brain barrier‐related proteins increases with severity of BBB damage. This highlights their potential as novel biomarkers for monitoring BBB integrity. Remarkably, the presence of high concentrations of Fibrinogen in the CSF could be an important feature to further investigate.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-12-01
DOI
https://doi.org/10.1002/alz.092219
Citations
1
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.36
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CSF profiling of impaired Blood‐brain barrier individuals: novel putative biomarkers discovery

Nicholas James Ashton, Henrik Zetterberg, Giovanni De Santis, Kaj Blennow
1 citations
Alzheimer s & Dementia
Computational Drug Discovery Methods
0.36
article

CSF profiling of impaired Blood‐brain barrier individuals: novel putative biomarkers discovery

Nicholas James Ashton, Henrik Zetterberg, Giovanni De Santis, Kaj Blennow
article en
1 citations

Abstract

Abstract Background Blood‐brain barrier (BBB) integrity is crucial for brain homeostasis and maintenance. This is a pilot study to investigate cerebrospinal fluid (CSF) levels of several proteins implicated in BBB integrity, such as aquaporin‐4 (AQP4), platelet‐derived growth factor (PDGFRβ), human major facilitator superfamily domain containing protein 2A (MFSD2A), matrix metalloproteinase (MMP)‐9, Matrix metalloproteinase (MMP)‐2, and Fibrinogen, for assessing BBB integrity. Method CSF samples were collected from 100 participants (36 [36%] female and 64 males [64%]; mean [SD] age, 73,34 [9,05] years). Participants were stratified according to their CSF/serum albumin concentration ratio (Q‐Alb); intact BBB (Q‐Alb <9, n = 25), mild BBB damage (Q‐Alb 9‐14, n = 25), modest BBB damage (Q‐Alb 14‐30, n = 24), and severe BBB damage (Q‐Alb >30, n = 25). AD CSF biomarkers (p‐Tau181, total‐Tau, Aβ42/40 ratio) were assessed by LUMIPULSE G1200. Protein levels were quantified using ELISA Kits (CUSABIO, Thermofisher, Bioss Antibodies). Correlation analyses were conducted between protein levels and albumin CSF/serum ratios with R (Kruskal‐Wallis test with pairwise comparison, Bonferroni method, was performed). Result CSF AQP4 and PDGFRβ levels were significantly higher in individuals with severe BBB damage (Figure 1). No significant differences are highlighted in the levels of MMP9, MMP2, MFSD2A and Fibrinogen; whereas, in both MFSD2A and Fibrinogen it is shown a notable difference in the levels of protein between the modest and intact groups, with a subsequent decline in the severe group. A positive correlation (Figure 2) between PDGFRB and AQP4 with Q‐Alb (PDGFRB, r = 0,273, P < 0,0001; AQP4, r = 038, P < 0,001) was found, where AQP4 seems to best reflect albumin stratification (Figure 3). Conclusion In this pilot study, we show that CSF concentration of some blood‐brain barrier‐related proteins increases with severity of BBB damage. This highlights their potential as novel biomarkers for monitoring BBB integrity. Remarkably, the presence of high concentrations of Fibrinogen in the CSF could be an important feature to further investigate.

Alzheimer s & DementiaVol. 20(S2)
University of Wisconsin–Madison (US), King's College London (GB), Sahlgrenska University Hospital (SE), UK Dementia Research Institute (GB), National Hospital for Neurology and Neurosurgery (GB), University College London (GB), University of Gothenburg (SE)
Openalex Percentile: Top 32%
Computational Drug Discovery Methods
0.36
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.